# A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

> **NCT03771664** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 87 (actual)

## Conditions studied

- Major Depressive Disorder
- Insomnia

## Interventions

- **DRUG:** SAGE-217
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03771664
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-04
- **Primary completion:** 2019-12-20
- **Final completion:** 2020-01-17
- **Target enrollment:** 87 (ACTUAL)
- **Why stopped:** internal company decision
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03771664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03771664, "A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03771664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*